Pasar al contenido principal

NANOCAPSULAS PLASMONICAS QUE ACTIVAN LA MUERTE INMUNOGENICA DE CELULAS TUMORALES MEDIANTE HYPERTERMIA PARA MEJORAR LA IMMUNOTERAPIA DEL CANCER

PID2022-140423NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks

  • Rodríguez-Gómez, Francisco D.
  • Monferrer, Dominique
  • Penon, Oriol
  • Rivera Gil, Pilar, 1976-
The integration of nanotechnology into healthcare has introduced Nanotechnology-Enabled Health Products (NHPs), promising revolutionary advancements in medical treatments and diagnostics. Despite their potential, the regulatory navigation for these products remains complex and often lagging, creating barriers to their clinical application. This review article focuses on dissecting the regulatory landscape for NHPs, particularly in the European Union and the United States, to identify applicable requirements and the main regulatory guidelines currently available for meeting regulatory expectations., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Industrial Doctorates Plan of the Department of Research and Universities of the Generalitat de Catalunya (Grant n° 202015). PRG acknowledges the Ministry of Science, Innovation and Universities (MICINN-AEI) (AEI-PID2022-140423NB-I00/AEI/10.13039/501100011033, CNS2023 - 143700) and the AGAUR (2021 SGR 00175 and 2021 PROD 00041) for financial support.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Implementing Horizon Scanning as a tool for the strategic development of regulatory guidelines for nanotechnology-enabled health products

  • Rodríguez-Gómez, Francisco D.
  • Monferrer, Dominique
  • Penon, Oriol
  • Rivera Gil, Pilar, 1976-
Strategic regulatory development is essential to ensure that new innovations in nanotechnology-enabled health products (NHPs) successfully reach the market and benefit patients. Currently, the lack of specific regulatory guidelines for NHPs is considered one of the primary causes of the so-called "valley of death" in these products, impacting both current and future advancements. In this study, we have implemented a methodology to anticipate key trends in NHP development and compare them with the current regulatory landscape applicable to NHPs. This methodology relies on Horizon Scanning, a tool commonly used by policymakers to foresee future needs and proactively shape a regulatory framework tailored to those needs. Through the application of this methodology, different trends in NHP have been identified, notably NHPs for drug delivery and dental applications. Furthermore, the most disruptive elements involve NHPs that are multicomposite and multifunctional, harnessing nano-scale properties to combine therapeutic and diagnostic purposes within a single product. When compared with the regulatory landscape, current regulations are gradually adapting to accommodate emerging trends, with specific guidelines being developed. However, for the most disruptive elements, multicomposite and multifunctional NHPs, their novelty still poses significant regulatory challenges, requiring a strategic development of guidelines by regulatory agencies to ensure their safe and effective integration into healthcare practices. This study underscores the importance of proactive regulatory planning to bridge the gap between NHP innovation and market implementation., This work was supported by the Industrial Doctorates Plan of the Department of Research and Universities of the Generalitat de Catalunya (grant no 202015). PRG acknowledges the Ministry of Science, Innovation and Universities (MICINN-AEI) (AEI-PID2019-106755RB-I00 and AEI-PID2022-140423NB-I00) and the AGAUR (2021 SGR 00175 and 2021 PROD 00041) for financial support.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Optical monitoring of labile zinc inside metastatic cells with plasmonic chemonanosensors

  • Zhou, Ting
  • Vicente García, Rubén, 1978-
  • Rivera Gil, Pilar, 1976-
We report the development and characterization of an optical nanosensor for the detection of labile zinc in biological environments. The readout is based on surface-enhanced Raman scattering promoted by a Raman reporter conjugated to the inner plasmonic cavity of hollow silica nanocapsules. We quantify Zn2+ by obtaining the ratio between a Zn2+-sensitive band and a Zn2+-insensitive band. The Raman reporter measures within the range from 10-5 to 10-11 M and exhibits a limit of detection of 10-11.72 M. The nanosensor discriminates between intracellular and extracellular Zn2+ concentrations., Pilar Rivera Gil acknowledges the Ministry of Science, Innovation and Universities (MICINN) and the AEI (AEI-PID2019-106755RB-I00 and PID2022-140423NB-I00) and the AGAUR (2021 SGR 00175 and 2021 PROD 00041) for financial support. T.Z. and Pilar Rivera Gil appreciate the financial support from the China Scholarship Council (CSC) by a State Scholarship Fund (NSCIS no. 202008350121). R.V. acknowledges AEI (PID2022-136511OB-I00) for financial support.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Validation of ZIP4 as a tumour-associated antigen for nanotargeting

  • Xu, Ruixue
  • Martínez Bosch, Neus
  • Rivera Hueto, Francisco
  • Mulens-Arias, Vladimir
  • Rubio Moscardó, Fanny
  • Conesa, José Javier
  • Navarro, Pilar
  • Vicente García, Rubén, 1978-
  • Rivera Gil, Pilar, 1976-
Pancreatic ductal adenocarcinoma remains a highly aggressive and untreatable cancer. There is a need to develop a new PDAC-associated antigen-targeting drug delivery system to tackle this disease. We validated choosing ZIP4 as a putative target in PDAC theranostics. We developed a nanosystem composed of a fluorescent polystyrene core coated with gold nanoparticles onto which a ZIP4-specific polyclonal antibody is attached. The polystyrene core's fluorescence properties allow the nanosystem tracking by intravital imaging. We also developed two ZIP4-expressing cell lines by stably transfecting HEK293 and RWP1 cells with a ZIP4-coding plasmid that simultaneously provides cells with puromycin resistance. We studied the cell internalisation of the as-synthesised nanoparticles and demonstrated that ZIP4-expressing HEK293 and ZIP4-expressing RWP1 cells tended to take up more ZIP4-targeting nanoparticles. Moreover, we observed that ZIP4-targeting nanoparticles accumulated more in ZIP4-expressing HEK293 and RWP1 tumours when injected intravenously in a subcutaneous xenograft and an orthotopic in vivo model, respectively. Furthermore, the administration of these nanoparticles did not induce any significant systemic toxicity as determined by histological analysis of all organs. Altogether, these results provide the first evidence of the feasibility of using a ZIP4-targeting nanosystem further to design efficient therapeutic and diagnostic tools for PDAC., Pilar Rivera Gil (PRG) acknowledges the Ministry of Science, Innovation and Universities (MICINN-AEI): CNS2023 - 143700 - MICIU/AEI/10.13039/501100011033/Unión Europea NextGenerationEU/PRTR and PID2022-140423NB-I00 for financial support. Rubén Vicente acknowledges the MICINN-AEI (PID2022-136511OB-I00). PRG acknowledges the AGAUR (Agència de Gestió d’Ajuts Universitaris i de Recerca) (2021 SGR 00175 and 2021 PROD 00041) for financial support. This work was also supported by grants from the Spanish Ministry of Science and Innovation (MICINN)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF) (PI20/00625 and PI23/00591) to Pilar Navarro.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Two photon-responsive gold nanocapsules enable targeted photothermal hyperthermia of chemoresistant melanoma: injection-route-dependent efficacy and renal evidence of fragment clearance

  • Zamora Pérez, Paula, 1988-
  • She, Qiutian
  • Santos, Harrisson D.
  • Conesa, José Javier
  • Iglesias de la Cruz, M. Carmen
  • Fernández, Nuria
  • Jaque, Daniel
  • Rivera Gil, Pilar, 1976-
Melanoma is a highly aggressive skin cancer that often develops resistance to chemotherapy, underscoring the need for new treatment strategies. Here we evaluate plasmonic gold nanocapsules (AuNCs) as photoresponsive agents for two-photon luminescence-assisted photothermal therapy in chemoresistant melanoma models. The performance of the AuNCs was assessed in two-dimensional cell cultures, three-dimensional paclitaxel-resistant B16-F10 melanoma spheroids, and a subcutaneous melanoma mouse model under near-infrared excitation. In vitro, AuNCs alone exhibited no cytotoxicity, but under 830 nm two-photon excitation, they produced strong two-photon luminescence and thermal effects that increased with nanocapsule concentration and laser power. This led to transient oxidative stress, apoptosis induction, and effective melanoma cell ablation under optimal conditions (80 μg mL-1 AuNCs, 12 mW laser power). In vivo, the route of nanoparticle administration proved decisive. A single 4-min 806 nm irradiation after intratumoral injection uniformly heated the lesion (≈45-50 °C), yielded durable tumour eradication, and sequestered >99% of detected gold in the necrotic scab, with only trace renal clearance. In contrast, the same laser fluence after peritumoral injection generated a superficial hot rim, spared the tumour core, allowing eventual regrowth, and left ∼65% of the injected gold systemically redistributed, mainly in the spleen and liver. These findings highlight the potential of AuNCs as potent, image-guided photothermal agents for chemoresistant melanoma, offering targeted tumor destruction with limited systemic exposure. They reveal the injection route is a critical determinant of both therapeutic success and nanoparticle biodistribution., The study of the nanophotothermal therapy (nPTT) effects of gold nanocapsules (AuNCs) on melanoma cells using cryo soft X-ray tomography (CSXT) was conducted at the MISTRAL beamline of the ALBA Synchrotron (Project number: 2016091853). PRG acknowledges the Ministry of Science, Innovation and Universities (AEI-PID2022-140423NB-I00/AEI/10.13039/501100011033 and CNS2023 – 143700) and the AGAUR (2021 SGR 00175) for financial support. D. Jaque acknowledges the Ministry of Science, Innovation and Universities of Spain (PID2023-146775OB-I00). The authors thank Dr Vladimir Mulens Arias for fruitful discussions and Alba Riba for her contribution (Fig. S2A, ESI†).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Validation of ZIP4 as a tumour-associated antigen for nanotargeting

  • Xu, Ruixue
  • Martínez-Bosch, Neus
  • Rivera-Hueto, Francisco
  • Mulens-Arias, Vladimir
  • Rubio-Moscardo, Fanny
  • Conesa, J. Javier
  • Navarro Medrano, Pilar
  • Vicente, Rubén
  • Rivera-Gil, Pilar
Pancreatic ductal adenocarcinoma remains a highly aggressive and untreatable cancer. There is a need to develop a new PDAC-associated antigen-targeting drug delivery system to tackle this disease. We validated choosing ZIP4 as a putative target in PDAC theranostics. We developed a nanosystem composed of a fluorescent polystyrene core coated with gold nanoparticles onto which a ZIP4-specific polyclonal antibody is attached. The polystyrene core's fluorescence properties allow the nanosystem tracking by intravital imaging. We also developed two ZIP4-expressing cell lines by stably transfecting HEK293 and RWP1 cells with a ZIP4-coding plasmid that simultaneously provides cells with puromycin resistance. We studied the cell internalisation of the as-synthesised nanoparticles and demonstrated that ZIP4-expressing HEK293 and ZIP4-expressing RWP1 cells tended to take up more ZIP4-targeting nanoparticles. Moreover, we observed that ZIP4-targeting nanoparticles accumulated more in ZIP4-expressing HEK293 and RWP1 tumours when injected intravenously in a subcutaneous xenograft and an orthotopic in vivo model, respectively. Furthermore, the administration of these nanoparticles did not induce any significant systemic toxicity as determined by histological analysis of all organs. Altogether, these results provide the first evidence of the feasibility of using a ZIP4-targeting nanosystem further to design efficient therapeutic and diagnostic tools for PDAC., The study by cryoSXT was performed at the MISTRAL beamline at ALBA Synchrotron with the collaboration of ALBA staff. N.M-B and P.N. belong to the Spanish National Research Council’s Cancer Hub (Conexión Cáncer-CSIC). The authors acknowledge Prof. A. Carrato and his group at IRYCIS for the scientific talks and the human ­tissue samples., Pilar Rivera Gil (PRG) acknowledges the Ministry of Science, Innovation and Universities (MICINN-AEI): CNS2023 - 143700 - MICIU/AEI/10.13039/501100011033/Unión Europea NextGenerationEU/PRTR and PID2022-140423NB-I00 for financial support. Rubén Vicente acknowledges the MICINN-AEI (PID2022-136511OB-I00). PRG acknowledges the AGAUR (Agència de Gestió d’Ajuts Universitaris i de Recerca) (2021 SGR 00175 and 2021 PROD 00041) for financial support. This work was also supported by grants from the Spanish Ministry of Science and Innovation (MICINN)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF) (PI20/00625 and PI23/00591) to Pilar Navarro., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Validation of ZIP4 as a tumour-associated antigen for nanotargeting [Dataset]

  • Xu, Ruixue
  • Martínez-Bosch, Neus
  • Rivera-Hueto, Francisco
  • Mulens-Arias, Vladimir
  • Rubio-Moscardo, Fanny
  • Conesa, J. Javier
  • Navarro Medrano, Pilar
  • Vicente, Rubén
  • Rivera-Gil, Pilar
Pancreatic ductal adenocarcinoma remains a highly aggressive and untreatable cancer. There is a need to develop a new PDAC-associated antigen-targeting drug delivery system to tackle this disease. We validated choosing ZIP4 as a putative target in PDAC theranostics. We developed a nanosystem composed of a fluorescent polystyrene core coated with gold nanoparticles onto which a ZIP4-specific polyclonal antibody is attached. The polystyrene core's fluorescence properties allow the nanosystem tracking by intravital imaging. We also developed two ZIP4-expressing cell lines by stably transfecting HEK293 and RWP1 cells with a ZIP4-coding plasmid that simultaneously provides cells with puromycin resistance. We studied the cell internalisation of the as-synthesised nanoparticles and demonstrated that ZIP4-expressing HEK293 and ZIP4-expressing RWP1 cells tended to take up more ZIP4-targeting nanoparticles. Moreover, we observed that ZIP4-targeting nanoparticles accumulated more in ZIP4-expressing HEK293 and RWP1 tumours when injected intravenously in a subcutaneous xenograft and an orthotopic in vivo model, respectively. Furthermore, the administration of these nanoparticles did not induce any significant systemic toxicity as determined by histological analysis of all organs. Altogether, these results provide the first evidence of the feasibility of using a ZIP4-targeting nanosystem further to design efficient therapeutic and diagnostic tools for PDAC., Pilar Rivera Gil (PRG) acknowledges the Ministry of Science, Innovation and Universities (MICINN-AEI): CNS2023 - 143700 - MICIU/AEI/10.13039/501100011033/Unión Europea NextGenerationEU/PRTR and PID2022-140423NB-I00 for financial support. Rubén Vicente acknowledges the MICINN-AEI (PID2022-136511OB-I00). PRG acknowledges the AGAUR (Agència de Gestió d’Ajuts Universitaris i de Recerca) (2021 SGR 00175 and 2021 PROD 00041) for financial support. This work was also supported by grants from the Spanish Ministry of Science and Innovation (MICINN)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF) (PI20/00625 and PI23/00591) to Pilar Navarro., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Optical monitoring of labile zinc inside metastatic cells with plasmonic chemonanosensors

  • Zhou, Ting
  • Vicente García, Rubén, 1978-
  • Rivera Gil, Pilar, 1976-
We report the development and characterization of an optical nanosensor for the detection of labile zinc in biological environments. The readout is based on surface-enhanced Raman scattering promoted by a Raman reporter conjugated to the inner plasmonic cavity of hollow silica nanocapsules. We quantify Zn2+ by obtaining the ratio between a Zn2+-sensitive band and a Zn2+-insensitive band. The Raman reporter measures within the range from 10-5 to 10-11 M and exhibits a limit of detection of 10-11.72 M. The nanosensor discriminates between intracellular and extracellular Zn2+ concentrations., Pilar Rivera Gil acknowledges the Ministry of Science, Innovation and Universities (MICINN) and the AEI (AEI-PID2019-106755RB-I00 and PID2022-140423NB-I00) and the AGAUR (2021 SGR 00175 and 2021 PROD 00041) for financial support. T.Z. and Pilar Rivera Gil appreciate the financial support from the China Scholarship Council (CSC) by a State Scholarship Fund (NSCIS no. 202008350121). R.V. acknowledges AEI (PID2022-136511OB-I00) for financial support.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks

  • Rodríguez-Gómez, Francisco D.
  • Monferrer, Dominique
  • Penon, Oriol
  • Rivera Gil, Pilar, 1976-
The integration of nanotechnology into healthcare has introduced Nanotechnology-Enabled Health Products (NHPs), promising revolutionary advancements in medical treatments and diagnostics. Despite their potential, the regulatory navigation for these products remains complex and often lagging, creating barriers to their clinical application. This review article focuses on dissecting the regulatory landscape for NHPs, particularly in the European Union and the United States, to identify applicable requirements and the main regulatory guidelines currently available for meeting regulatory expectations., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Industrial Doctorates Plan of the Department of Research and Universities of the Generalitat de Catalunya (Grant n° 202015). PRG acknowledges the Ministry of Science, Innovation and Universities (MICINN-AEI) (AEI-PID2022-140423NB-I00/AEI/10.13039/501100011033, CNS2023 - 143700) and the AGAUR (2021 SGR 00175 and 2021 PROD 00041) for financial support.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Validation of ZIP4 as a tumour-associated antigen for nanotargeting

  • Xu, Ruixue
  • Martínez Bosch, Neus
  • Rivera Hueto, Francisco
  • Mulens-Arias, Vladimir
  • Rubio Moscardó, Fanny
  • Conesa, José Javier
  • Navarro, Pilar
  • Vicente García, Rubén, 1978-
  • Rivera Gil, Pilar, 1976-
Pancreatic ductal adenocarcinoma remains a highly aggressive and untreatable cancer. There is a need to develop a new PDAC-associated antigen-targeting drug delivery system to tackle this disease. We validated choosing ZIP4 as a putative target in PDAC theranostics. We developed a nanosystem composed of a fluorescent polystyrene core coated with gold nanoparticles onto which a ZIP4-specific polyclonal antibody is attached. The polystyrene core's fluorescence properties allow the nanosystem tracking by intravital imaging. We also developed two ZIP4-expressing cell lines by stably transfecting HEK293 and RWP1 cells with a ZIP4-coding plasmid that simultaneously provides cells with puromycin resistance. We studied the cell internalisation of the as-synthesised nanoparticles and demonstrated that ZIP4-expressing HEK293 and ZIP4-expressing RWP1 cells tended to take up more ZIP4-targeting nanoparticles. Moreover, we observed that ZIP4-targeting nanoparticles accumulated more in ZIP4-expressing HEK293 and RWP1 tumours when injected intravenously in a subcutaneous xenograft and an orthotopic in vivo model, respectively. Furthermore, the administration of these nanoparticles did not induce any significant systemic toxicity as determined by histological analysis of all organs. Altogether, these results provide the first evidence of the feasibility of using a ZIP4-targeting nanosystem further to design efficient therapeutic and diagnostic tools for PDAC., Pilar Rivera Gil (PRG) acknowledges the Ministry of Science, Innovation and Universities (MICINN-AEI): CNS2023 - 143700 - MICIU/AEI/10.13039/501100011033/Unión Europea NextGenerationEU/PRTR and PID2022-140423NB-I00 for financial support. Rubén Vicente acknowledges the MICINN-AEI (PID2022-136511OB-I00). PRG acknowledges the AGAUR (Agència de Gestió d’Ajuts Universitaris i de Recerca) (2021 SGR 00175 and 2021 PROD 00041) for financial support. This work was also supported by grants from the Spanish Ministry of Science and Innovation (MICINN)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF) (PI20/00625 and PI23/00591) to Pilar Navarro.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Two photon-responsive gold nanocapsules enable targeted photothermal hyperthermia of chemoresistant melanoma: injection-route-dependent efficacy and renal evidence of fragment clearance

  • Zamora Pérez, Paula, 1988-
  • She, Qiutian
  • Santos, Harrisson D.
  • Conesa, José Javier
  • Iglesias de la Cruz, M. Carmen
  • Fernández, Nuria
  • Jaque, Daniel
  • Rivera Gil, Pilar, 1976-
Melanoma is a highly aggressive skin cancer that often develops resistance to chemotherapy, underscoring the need for new treatment strategies. Here we evaluate plasmonic gold nanocapsules (AuNCs) as photoresponsive agents for two-photon luminescence-assisted photothermal therapy in chemoresistant melanoma models. The performance of the AuNCs was assessed in two-dimensional cell cultures, three-dimensional paclitaxel-resistant B16-F10 melanoma spheroids, and a subcutaneous melanoma mouse model under near-infrared excitation. In vitro, AuNCs alone exhibited no cytotoxicity, but under 830 nm two-photon excitation, they produced strong two-photon luminescence and thermal effects that increased with nanocapsule concentration and laser power. This led to transient oxidative stress, apoptosis induction, and effective melanoma cell ablation under optimal conditions (80 μg mL-1 AuNCs, 12 mW laser power). In vivo, the route of nanoparticle administration proved decisive. A single 4-min 806 nm irradiation after intratumoral injection uniformly heated the lesion (≈45-50 °C), yielded durable tumour eradication, and sequestered >99% of detected gold in the necrotic scab, with only trace renal clearance. In contrast, the same laser fluence after peritumoral injection generated a superficial hot rim, spared the tumour core, allowing eventual regrowth, and left ∼65% of the injected gold systemically redistributed, mainly in the spleen and liver. These findings highlight the potential of AuNCs as potent, image-guided photothermal agents for chemoresistant melanoma, offering targeted tumor destruction with limited systemic exposure. They reveal the injection route is a critical determinant of both therapeutic success and nanoparticle biodistribution., The study of the nanophotothermal therapy (nPTT) effects of gold nanocapsules (AuNCs) on melanoma cells using cryo soft X-ray tomography (CSXT) was conducted at the MISTRAL beamline of the ALBA Synchrotron (Project number: 2016091853). PRG acknowledges the Ministry of Science, Innovation and Universities (AEI-PID2022-140423NB-I00/AEI/10.13039/501100011033 and CNS2023 – 143700) and the AGAUR (2021 SGR 00175) for financial support. D. Jaque acknowledges the Ministry of Science, Innovation and Universities of Spain (PID2023-146775OB-I00). The authors thank Dr Vladimir Mulens Arias for fruitful discussions and Alba Riba for her contribution (Fig. S2A, ESI†).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Implementing Horizon Scanning as a tool for the strategic development of regulatory guidelines for nanotechnology-enabled health products

  • Rodríguez-Gómez, Francisco D.
  • Monferrer, Dominique
  • Penon, Oriol
  • Rivera Gil, Pilar, 1976-
Strategic regulatory development is essential to ensure that new innovations in nanotechnology-enabled health products (NHPs) successfully reach the market and benefit patients. Currently, the lack of specific regulatory guidelines for NHPs is considered one of the primary causes of the so-called "valley of death" in these products, impacting both current and future advancements. In this study, we have implemented a methodology to anticipate key trends in NHP development and compare them with the current regulatory landscape applicable to NHPs. This methodology relies on Horizon Scanning, a tool commonly used by policymakers to foresee future needs and proactively shape a regulatory framework tailored to those needs. Through the application of this methodology, different trends in NHP have been identified, notably NHPs for drug delivery and dental applications. Furthermore, the most disruptive elements involve NHPs that are multicomposite and multifunctional, harnessing nano-scale properties to combine therapeutic and diagnostic purposes within a single product. When compared with the regulatory landscape, current regulations are gradually adapting to accommodate emerging trends, with specific guidelines being developed. However, for the most disruptive elements, multicomposite and multifunctional NHPs, their novelty still poses significant regulatory challenges, requiring a strategic development of guidelines by regulatory agencies to ensure their safe and effective integration into healthcare practices. This study underscores the importance of proactive regulatory planning to bridge the gap between NHP innovation and market implementation., This work was supported by the Industrial Doctorates Plan of the Department of Research and Universities of the Generalitat de Catalunya (grant no 202015). PRG acknowledges the Ministry of Science, Innovation and Universities (MICINN-AEI) (AEI-PID2019-106755RB-I00 and AEI-PID2022-140423NB-I00) and the AGAUR (2021 SGR 00175 and 2021 PROD 00041) for financial support.